Paul Hofman Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice Université Côte d’Azur, CHU de Nice Biography Publications Institution JoVE Articles Paul Hofman has not added a biography. If you are Paul Hofman and would like to personalize this page please email our Author Liaison for assistance. Publications The Need to Set Up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte D'Azur, Nice, France) Journal of Personalized Medicine. Jun, 2023 | Pubmed ID: 37511690 Should Evidence of an Autolysosomal De-acidification Defect in Alzheimer and Parkinson Diseases Call for Caution in Prescribing Chronic PPI and DMARD? Autophagy. Oct, 2023 | Pubmed ID: 37482676 Matched Tissue and Liquid Biopsies for Advanced Non-small Cell Lung Cancer Patients A Potentially Indispensable Complementary Approach Translational Oncology. Sep, 2023 | Pubmed ID: 37413719 Quantitative Multiplexed Imaging Technologies for Single-cell Analysis to Assess Predictive Markers for Immunotherapy in Thoracic Immuno-oncology: Promises and Challenges British Journal of Cancer. Jun, 2023 | Pubmed ID: 37391504 Cholesterol Efflux Pathways Hinder KRAS-driven Lung Tumor Progenitor Cell Expansion Cell Stem Cell. Jun, 2023 | Pubmed ID: 37267915 The Significance of Co-mutations in EGFR-mutated Non-small Cell Lung Cancer: Optimizing the Efficacy of Targeted Therapies? Lung Cancer (Amsterdam, Netherlands). Jul, 2023 | Pubmed ID: 37244040 Lack of Correlation Between MET and PD-L1 Expression in Non-small Cell Lung Cancer Revealed by Comparative Study of Matched Biopsies and Surgical Resection Samples Lung Cancer (Amsterdam, Netherlands). Jul, 2023 | Pubmed ID: 37150140 Host Genetic Variability and Determinants of Severe COVID-19 Trends in Genetics : TIG. Mar, 2023 | Pubmed ID: 36379742 Epithelial-to-mesenchymal Transition Promotes Immune Escape by Inducing CD70 in Non-small Cell Lung Cancer European Journal of Cancer (Oxford, England : 1990). Jul, 2022 | Pubmed ID: 35550950 Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is Synergistically Associated with T Cell Exclusion, Immune Checkpoint Blockade Efficacy and Recurrence Risk in ER-negative Breast Cancer Cellular Oncology (Dordrecht). Jun, 2022 | Pubmed ID: 35543859 Autophagopathies: from Autophagy Gene Polymorphisms to Precision Medicine for Human Diseases Autophagy. Nov, 2022 | Pubmed ID: 35383530 Analytical Validation of Automated Multiplex Chromogenic Immunohistochemistry for Diagnostic and Predictive Purpose in Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Apr, 2022 | Pubmed ID: 35134710 Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis That Contributes to Carcinogenesis Cancer Discovery. Apr, 2022 | Pubmed ID: 34930787 Salivary Detection of COVID-19: Clinical Performance of Oral Sponge Sampling for SARS-CoV-2 Testing ERJ Open Research. Oct, 2021 | Pubmed ID: 34877351 A Rapid Near-patient RT-PCR Test for Suspected COVID-19: a Study of the Diagnostic Accuracy Annals of Translational Medicine. Jun, 2021 | Pubmed ID: 34350236 The Carcinogen Cadmium Activates Lysine 63 (K63)-Linked Ubiquitin-Dependent Signaling and Inhibits Selective Autophagy Cancers. May, 2021 | Pubmed ID: 34065348 Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. May, 2021 | Pubmed ID: 33545389 [Histopathological Features Due to the SARS-CoV-2] Annales De Pathologie. Feb, 2021 | Pubmed ID: 33446414 Clinical and Molecular Practice of European Thoracic Pathology Laboratories During the COVID-19 Pandemic. The Past and the Near Future ESMO Open. Feb, 2021 | Pubmed ID: 33399086 Using Genetics To Dissect SARS-CoV-2 Infection Trends in Genetics : TIG. Mar, 2021 | Pubmed ID: 33309104 Open Questions for Harnessing Autophagy-modulating Drugs in the SARS-CoV-2 War: Hope or Hype? Autophagy. Dec, 2020 | Pubmed ID: 32521191 Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. Sep, 2020 | Pubmed ID: 32450274 Real-world Assessment of the BRAF Status in Non-squamous Cell Lung Carcinoma Using VE1 Immunohistochemistry: A Single Laboratory Experience (LPCE, Nice, France) Lung Cancer (Amsterdam, Netherlands). Jul, 2020 | Pubmed ID: 32408133 Possible Consequences of the COVID-19 Pandemic on the Use of Biospecimens from Cancer Biobanks for Research in Academia and Bioindustry Nature Medicine. Jun, 2020 | Pubmed ID: 32382152 Prospective Evaluation of NGS-based Liquid Biopsy in Untreated Late Stage Non-squamous Lung Carcinoma in a Single Institution Journal of Translational Medicine. Feb, 2020 | Pubmed ID: 32066459 Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France) Clinical Lung Cancer. Jan, 2020 | Pubmed ID: 31519454 EGFR Mutation Analysis in Non-small Cell Lung Carcinoma from Tissue Samples Using the Fully Automated Idylla™ QPCR System Methods in Molecular Biology (Clifton, N.J.). 2019 | Pubmed ID: 31482454 In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients Cancers. Aug, 2019 | Pubmed ID: 31470674 Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment Cells. Jul, 2019 | Pubmed ID: 31337010 [Pseudo-tumor Lesions Induced by Infectious Agents. Case No. 8] Annales De Pathologie. Aug, 2019 | Pubmed ID: 31255414 [Pseudo-tumor Lesions Induced by Infectious Agents. Case No. 7] Annales De Pathologie. Aug, 2019 | Pubmed ID: 31255413 Liquid Biopsy in the Era of Immuno-oncology: is It Ready for Prime-time Use for Cancer Patients? Annals of Oncology : Official Journal of the European Society for Medical Oncology. Sep, 2019 | Pubmed ID: 31228184 [Pseudotumor Lesions Induced by Infectious Agents. Introduction] Annales De Pathologie. Aug, 2019 | Pubmed ID: 31003708 [Tumor Banks and Complex Data Management: Current and Future Challenges] Annales De Pathologie. Apr, 2019 | Pubmed ID: 30819623 [The Age of Artificial Intelligence in Lung Cancer Pathology: Between Hope, Gloom and Perspectives] Annales De Pathologie. Apr, 2019 | Pubmed ID: 30772062 Lung Cancer Screening, Towards a Multidimensional Approach: Why and How? Cancers. Feb, 2019 | Pubmed ID: 30759893 Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma Cancers. Sep, 2018 | Pubmed ID: 30216999 Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How? Cancers. Jun, 2018 | Pubmed ID: 29966305 Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections Through the Encapsulation of Dried DNA Cancers. Jun, 2018 | Pubmed ID: 29891792 Effect of Mutant Variants of the KRAS Gene on PD-L1 Expression and on the Immune Microenvironment and Association with Clinical Outcome in Lung Adenocarcinoma Patients Lung Cancer (Amsterdam, Netherlands). Jul, 2018 | Pubmed ID: 29858030 E2F1 Inhibition Mediates Cell Death of Metastatic Melanoma Cell Death & Disease. 05, 2018 | Pubmed ID: 29743521 Rapid Decay of Engulfed Extracellular MiRNA by XRN1 Exonuclease Promotes Transient Epithelial-mesenchymal Transition Nucleic Acids Research. Apr, 2018 | Pubmed ID: 29562367 Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients Cancers. Mar, 2018 | Pubmed ID: 29561830 Any Place for Immunohistochemistry Within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers. Mar, 2018 | Pubmed ID: 29534030 Use of Circulating Tumor Cells in Prospective Clinical Trials for NSCLC Patients - Standardization of the Pre-analytical Conditions Clinical Chemistry and Laboratory Medicine. May, 2018 | Pubmed ID: 29397019 Reproducibility of PD-L1 Assessment in Non-small Cell Lung Cancer-know Your Limits but Never Stop Trying to Exceed Them Translational Lung Cancer Research. Dec, 2017 | Pubmed ID: 29299411 Circulating Tumour Cells As a Potential Screening Tool for Lung Cancer (the AIR Study): Protocol of a Prospective Multicentre Cohort Study in France BMJ Open. 12, 2017 | Pubmed ID: 29282271 Atezolizumab in Advanced Non-small Cell Lung Cancer Journal of Thoracic Disease. Oct, 2017 | Pubmed ID: 29268352 Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology Cancers. Nov, 2017 | Pubmed ID: 29125548 Response to First Line Chemotherapy Regimen is Associated with Efficacy of Nivolumab in Non-small-cell Lung Cancer Oncoimmunology. 2017 | Pubmed ID: 28932641 MiR-223-3p Inhibits Angiogenesis and Promotes Resistance to Cetuximab in Head and Neck Squamous Cell Carcinoma Oncotarget. Aug, 2017 | Pubmed ID: 28915663 ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice Cancers. Aug, 2017 | Pubmed ID: 28805682 ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients Cancers. Aug, 2017 | Pubmed ID: 28805673 Use of the 22C3 Anti-PD-L1 Antibody to Determine PD-L1 Expression in Multiple Automated Immunohistochemistry Platforms PloS One. 2017 | Pubmed ID: 28797130 Annales De Pathologie. Aug, 2017 | Pubmed ID: 28778623 Expression of MET in Circulating Tumor Cells Correlates with Expression in Tumor Tissue from Advanced-stage Lung Cancer Patients Oncotarget. Apr, 2017 | Pubmed ID: 28212540 Pathology of Infectious Diseases: What Does the Future Hold? Virchows Archiv : an International Journal of Pathology. May, 2017 | Pubmed ID: 28188440 [PD1/PD-L1 Immunohistochemistry in Thoracic Oncology: Where Are We?] Annales De Pathologie. Feb, 2017 | Pubmed ID: 28159404 Fibronectin-guided Migration of Carcinoma Collectives Nature Communications. Jan, 2017 | Pubmed ID: 28102238 Rapid Decay of Engulfed Extracellular MiRNA by XRN1 Exonuclease Promotes Transient Epithelial-mesenchymal Transition Nucleic Acids Research. Apr, 2017 | Pubmed ID: 27994032 Pathologists and Liquid Biopsies: to Be or Not to Be? Virchows Archiv : an International Journal of Pathology. Dec, 2016 | Pubmed ID: 27553354 [Issues and Current Limits for Immunohistochemical Assessment of PD-L1 status in Bronchial Biopsies] Bulletin Du Cancer. Apr, 2016 | Pubmed ID: 26920041 Assessment of the PD-L1 Status by Immunohistochemistry: Challenges and Perspectives for Therapeutic Strategies in Lung Cancer Patients Virchows Archiv : an International Journal of Pathology. May, 2016 | Pubmed ID: 26915032 Comparative Study of the PD-L1 Status Between Surgically Resected Specimens and Matched Biopsies of NSCLC Patients Reveal Major Discordances: a Potential Issue for Anti-PD-L1 Therapeutic Strategies Annals of Oncology : Official Journal of the European Society for Medical Oncology. Jan, 2016 | Pubmed ID: 26483045 Sense and Nonsense in the Process of Accreditation of a Pathology Laboratory Virchows Archiv : an International Journal of Pathology. Jan, 2016 | Pubmed ID: 26334197 [Search for Circulating Tumor Cells: Seriously, a Real Cancer Screening Tool?] Journal Des Maladies Vasculaires. Dec, 2015 | Pubmed ID: 26526763 Reply to the Letter to the Editor 'ALK FISH Rearranged and Amplified Tumor with Negative Immunohistochemistry: a Rare and Challenging Case Concerning ALK Status Screening in Lung Cancer' by Uguen Et Al Annals of Oncology : Official Journal of the European Society for Medical Oncology. Aug, 2015 | Pubmed ID: 25957328 KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives Current Molecular Medicine. 2015 | Pubmed ID: 25941815 Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer (Video) | JoVE Christophe Bontoux1,2,3,4,5, Virginie Lespinet-Fabre1,2,3,4, Olivier Bordone1,2,3,4, Virginie Tanga1,2,3,4, Maryline Allegra1,2,3,4, Myriam Salah1,2,3,4, Salomé Lalvée1,2,3,4, Samantha Goffinet1,2,3,4, Jonathan Benzaquen3,4,5,6, Charles-Hugo Marquette3,4,5,6, Marius Ilié1,2,3,4,5, Véronique Hofman1,2,3,4,5, Paul Hofman1,2,3,4,5 1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur JoVE 65190 Biologia Ved hjælp af 22C 3 Anti-PD-L1 antistof koncentrere sig om biopsi og cytologi prøver fra patienter med ikke-småcellet lungecancer Marius Ilié1,2,3, Mélanie Ngo-Mai1, Elodie Long-Mira1,2, Sandra Lassalle1,2, Catherine Butori1, Coraline Bence1, Marame Hamila1, Véronique Hofman1,2,3, Paul Hofman1,2,3 1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur JoVE 58082 Pesquisa do câncer
Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer (Video) | JoVE Christophe Bontoux1,2,3,4,5, Virginie Lespinet-Fabre1,2,3,4, Olivier Bordone1,2,3,4, Virginie Tanga1,2,3,4, Maryline Allegra1,2,3,4, Myriam Salah1,2,3,4, Salomé Lalvée1,2,3,4, Samantha Goffinet1,2,3,4, Jonathan Benzaquen3,4,5,6, Charles-Hugo Marquette3,4,5,6, Marius Ilié1,2,3,4,5, Véronique Hofman1,2,3,4,5, Paul Hofman1,2,3,4,5 1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur JoVE 65190 Biologia
Ved hjælp af 22C 3 Anti-PD-L1 antistof koncentrere sig om biopsi og cytologi prøver fra patienter med ikke-småcellet lungecancer Marius Ilié1,2,3, Mélanie Ngo-Mai1, Elodie Long-Mira1,2, Sandra Lassalle1,2, Catherine Butori1, Coraline Bence1, Marame Hamila1, Véronique Hofman1,2,3, Paul Hofman1,2,3 1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur JoVE 58082 Pesquisa do câncer